Efficacy of RSV Vaccine against Clinical Isolates
Author Information
Author(s): Jang Ji-Eun, Lee Jee-Boong, Kim Kyung-Hyo, Park Sung Moo, Shim Byoung-Shik, Cheon In Soo, Song Man Ki, Chang Jun
Primary Institution: Ewha Womans University, Seoul, Korea
Hypothesis
Can the recombinant adenovirus-based RSV vaccine candidate provide cross-protective efficacy against HRSV-A and HRSV-B isolates?
Conclusion
The RSV vaccine rAd/3xG provides complete protection against HRSV-A and partial protection against HRSV-B in mice.
Supporting Evidence
- A single intranasal immunization with rAd/3xG protected the mice completely from KR/A/09-8 infection.
- The vaccine provided partial protection against KR/B/10-12 infection.
- All HRSV-B isolates exhibited unique genetic changes.
- 30% of nasopharyngeal samples tested positive for HRSV.
Takeaway
Researchers tested a new RSV vaccine on mice and found it works really well against one type of the virus and okay against another type.
Methodology
The study involved collecting nasopharyngeal samples from pediatric patients, detecting HRSV using RT-PCR, and testing the vaccine's efficacy in mice.
Limitations
The study may not account for all circulating genetic variants of HRSV in Korea.
Participant Demographics
Children under 3 years of age admitted with acute lower respiratory tract infection.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website